- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00023413
TBTC Study 23C: Pharmacokinetics of Intermittent Rifabutin and Isoniazid With Daily Efavirenz
TBTC Study 23C: Intensive Pharmacokinetic Study of Intermittent Rifabutin and Isoniazid With Daily Efavirenz in Combination With Two Nucleoside Analogs for Treatment of HIV and Tuberculosis Co-infections
The aim of this trial is to study the efavirenz-rifabutin interaction. Thus, this trial will enroll patients with HIV and tuberculosis co-infections who are receiving a rifabutin-based regimen and who plan to begin an antiretroviral regimen containing efavirenz dosed at 600 mg daily. Enrollment in TB Trials Consortium Study 23 is not a requirement for participation in this study.
Primary Objective:
To compare the pharmacokinetics of rifabutin at 600 mg twice a week in combination with efavirenz 600 mg daily to the pharmacokinetics of rifabutin 300 mg twice a week without efavirenz.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
British Columbia
-
Vancouver, British Columbia, Canada, Canada V5Z 4R4
- University of British Columbia
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, CANADA R3A 1R8
- University of Manitoba
-
-
Quebec
-
Montreal, Quebec, Canada, H2X 2P4Pq Canada
- Montreal Chest Institute McGill University
-
-
-
-
Arkansas
-
Little Rock, Arkansas, Forenede Stater, 72205
- Central Arkansas Veterans Health System
-
-
California
-
Los Angeles, California, Forenede Stater, 90033
- LA County/USC Medical Center
-
San Francisco, California, Forenede Stater, 94110
- University of California, San Francisco
-
-
Colorado
-
Denver, Colorado, Forenede Stater, 80204
- Denver Department of Public Health and Hospitals
-
-
District of Columbia
-
Washington, District of Columbia, Forenede Stater, 20422
- Washington, D.C. VAMC
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60611
- Chicago VA Medical Center (Lakeside)
-
Hines, Illinois, Forenede Stater, 60141
- Hines VA Medical Center
-
-
Maryland
-
Baltimore, Maryland, Forenede Stater, 21287-0003
- Johns Hopkins University School Of Medicine
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02118
- Boston Medical Center
-
-
New Jersey
-
Newark, New Jersey, Forenede Stater, 07107-3001
- New Jersey Medical School
-
-
New York
-
New York, New York, Forenede Stater, 10016
- New York University School of Medicine
-
New York, New York, Forenede Stater, 10037
- Harlem Hospital Center
-
New York, New York, Forenede Stater, 10032
- Columbia University/Presbyterian Medical Center
-
-
North Carolina
-
Charlotte, North Carolina, Forenede Stater, 28203
- Carolinas Medical Center
-
Durham, North Carolina, Forenede Stater, 34222
- Duke University Medical Center
-
-
Tennessee
-
Nashville, Tennessee, Forenede Stater, 37212-2637
- Nashville VA Medical Center
-
-
Texas
-
Fort Worth, Texas, Forenede Stater, 76107-2699
- University of North Texas Health Science Center
-
Houston, Texas, Forenede Stater, 77009
- Thomas Street Clinic
-
San Antonio, Texas, Forenede Stater, 78284
- Audi L. Murphy VA Hospital
-
-
Washington
-
Seattle, Washington, Forenede Stater, 98104
- Seattle King County Health Department
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
- Patients with HIV and tuberculosis co-infections who are receiving a rifabutin-based regimen and who plan to begin an antiretroviral regimen containing efavirenz dosed at 600 mg daily.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
|---|
|
Compare PK of rifabutin 600mg twice weekly with efavirenz 600mg daily to PK of rifabutin 300mg twice weekly without efavirenz
|
Sekundære resultatmål
Resultatmål |
|---|
|
*Describe PK of rifabutin 600mg twice weekly in combination with efavirenz 600mg daily with 2 NRTI's
|
|
*Describe PK of efavirenz in this regimen
|
|
*Assess safety of concomitant rifabutin and efavirenz in HIV-TB
|
Samarbejdspartnere og efterforskere
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Marc Weiner, MD, San Antonio VAMC, San Antonio TX
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Bakterielle infektioner
- Bakterielle infektioner og mykoser
- Gram-positive bakterielle infektioner
- Actinomycetales infektioner
- Mycobacterium infektioner
- Infektioner
- Tuberkulose
- Molekylære mekanismer for farmakologisk virkning
- Anti-infektionsmidler
- Antivirale midler
- Reverse transkriptasehæmmere
- Nukleinsyresyntesehæmmere
- Enzymhæmmere
- Antibakterielle midler
- Cytokrom P-450 enzymhæmmere
- Cytokrom P-450 enzyminducere
- Cytokrom P-450 CYP3A inducere
- Antituberkulære midler
- Antibiotika, Antituberkulær
- Cytokrom P-450 CYP2B6 inducere
- Cytokrom P-450 CYP2C9-hæmmere
- Cytokrom P-450 CYP2C19-hæmmere
- Rifabutin
- Efavirenz
Andre undersøgelses-id-numre
- CDC-NCHSTP-2588
- 23C
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .